Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response

European Journal of Haematology

Volumn 86, Issue 6, 2011, Pages 541-545

  Takamatsu, Hiroyuki ^a   Yagasaki, Hiroshi ^b   Takahashi, Yoshiyuki ^c   Hama, Asahito ^c   Saikawa, Yutaka ^d   Yachie, Akihiro ^a   Koizumi, Shoichi ^a   Kojima, Seiji ^c   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Aplastic anemia; Autoantibody; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARDIOLIPIN ANTIBODY; CD20 ANTIBODY; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; LYMPHOGLOBULINE; METHYLPREDNISOLONE; MOESIN; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB; SINGLE STRANDED DNA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; APLASTIC ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CASE REPORT; DISEASE ASSOCIATION; DRUG MEGADOSE; ENTERITIS; FEVER; HUMAN; HYPOPLASIA; INFANT; INFORMED CONSENT; KARYOTYPE 46,XY; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MEGAKARYOPOIESIS; NEUTROPHIL COUNT; PANCYTOPENIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANEMIA, APLASTIC; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTILYMPHOCYTE SERUM; AUTOANTIBODIES; BIOLOGICAL MARKERS; BONE MARROW; CARBON-CARBON DOUBLE BOND ISOMERASES; CYCLOSPORINE; HUMANS; INFANT; MALE; MICROFILAMENT PROTEINS; REMISSION INDUCTION; T-LYMPHOCYTES;

EID: 79956034345     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01612.x     Document Type: Article

References (29)

1. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-61.
2. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
3. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007;136:451-61.
4. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004.
5. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009;114:3167-72.
6. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010;47:170-9.
7. Feng X, Chuhjo T, Sugimori C, Kotani T, Lu X, Takami A, Takamatsu H, Yamazaki H, Nakao S. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2004;104:2425-31.
8. Takamatsu H, Feng X, Chuhjo T, Lu X, Sugimori C, Okawa K, Yamamoto M, Iseki S, Nakao S. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood 2007;109:2514-20.
9. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, Sugita K, Yabe H, Ohara A, Tsukimoto I. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049-54.
10. Viale M, Merli A, Bacigalupo A. Analysis at the clonal level of T-cell phenotype and functions in severe aplastic anemia patients. Blood 1991;78:1268-74.
11. Zoumbos NC, Gascon P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med 1985;312:257-65.
12. Herrmann F, Griffin JD, Meuer SG, Meyer zum Buschenfelde KH. Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis. J Immunol 1986;136:1629-34.
13. Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol 2000;37:3-14.
14. Hara T, Ando K, Tsurumi H, Moriwaki H. Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia. Eur J Haematol 2004;73:10-6.
15. Dubey S, Shukla P, Nityanand S. Expression of interferon-gamma and tumor necrosis factor-alpha in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia. Ann Hematol 2005;84:572-7.
16. Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 1995;85:1348-53.
17. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995;85:3058-65.
18. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42.
19. Hansen PB, Lauritzen AM. Aplastic anemia successfully treated with rituximab. Am J Hematol 2005;80:292-4.
20. Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010;149:3-13.
21. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007;110:2924-30.
22. Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147-50.
23. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123:66-73.
24. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, Malmstrom V, Trollmo C. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122:62-74.
25. Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O'Connor KC, Schur PH, Kojima S, Guinan EC, Nadler LM. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003;102:4567-75.
26. Hirano N, Butler MO, Guinan EC, Nadler LM, Kojima S. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol 2005;128:221-3.
27. Qi Z, Takamatsu H, Espinoza JL, Lu X, Sugimori N, Yamazaki H, Okawa K, Nakao S. Autoantibodies specific to hnRNP K: a new diagnostic marker for immune pathophysiology in aplastic anemia. Ann Hematol 2010;89:1255-63.
28. Espinoza JL, Takamatsu H, Lu X, Qi Z, Nakao S. Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-alpha through an ERK1/2-dependent pathway. Int Immunol 2009;21:913-23.
29. Takamatsu H, Espinoza JL, Lu X, Qi Z, Okawa K, Nakao S. Anti-moesin antibodies in the serum of patients with aplastic anemia stimulate peripheral blood mononuclear cells to secrete TNF-alpha and IFN-gamma. J Immunol 2009;182:703-10.